Back to search
Recurrent Platinum-Resistant Fallopian Tube Carcinoma
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Recurrent Platinum-Resistant Fallopian Tube Carcinoma trials may be worth asking aboutClinical trial pipeline · Data from ClinicalTrials.gov
See which Recurrent Platinum-Resistant Fallopian Tube Carcinoma trials may be worth asking aboutNorth America
Europe
Asia-Pacific
Rest of World
Trials may have sites in multiple countries. Filtering shows any trial with at least one site in the selected country.
The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherap…
This trial is a registered, phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with platinum-resis…
This phase II trial studies the side effects of ONC201 and paclitaxel and how well they work in treating patients with platinum-resistant epithelial ovarian, fa…
This phase II trial tests whether pembrolizumab combined with bevacizumab with or without agonist anti-CD40 CDX-1140 works to shrink tumors in patients with ova…
To evaluate the efficacy and safety of B013 in patients with platinum-resistant recurrent ovarian cancer.
This phase I trial tests the safety, side effects, best dose of MUC1-activated T cells in treating patients with ovarian cancer that has come back after a perio…
This randomized phase II trial studies how well ATR kinase inhibitor M6620 (M6620) and gemcitabine hydrochloride work compared to standard treatment with gemcit…
This phase II trial studies how well durvalumab and tremelimumab work in treating participants with ovarian, primary peritoneal, or fallopian tube cancer that h…